Skin and Joints Podcast cover art

Skin and Joints Podcast

Skin and Joints Podcast

By: Mimi Tran Aaron Sihota Danny Mansour Ashley Yip Julia Tan Touraj Khosravi Anastasiya Muntyanu
Listen for free

Summary

 A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.2026 Skin and Joints Podcast Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • When Isotretinoin Isn’t Flying Solo: The Case for Combo Topical Acne Care at AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz

    When Isotretinoin Isn’t Flying Solo: The Case for Combo Topical Acne Care at AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz
    Apr 15 2026

    🎙️✨ Isotretinoin + Clascoterone: Acne’s New Power Couple?

    When acne gets severe, isotretinoin usually enters the chat as the big gun.💥
    But what happens when you pair it with topical clascoterone — the anti-androgen sidekick targeting the sebaceous gland from another angle?

    In this episode, we break down new real-world data from a multi-centre retrospective study comparing oral isotretinoin monotherapy versus combination isotretinoin + topical clascoterone for severe acne vulgaris and what the implications are for clinic.

    And yes — the combo arm brought some serious main-character energy.

    Our expert guests unpack what this could mean in clinic:
    ✨ faster clearance
    ✨ improved tolerability
    ✨ hormonal acne considerations
    ✨ patient adherence realities
    ✨ the ever-important goal of preventing scars before they happen

    Because in acne care, almost clear is nice… but clear-clear is the assignment. ✅

    This conversation dives into the practical side: When should clascoterone be added? Which patients may benefit most? How do we keep regimens simple for younger patients already juggling isotretinoin, labs, moisturizers, sunscreen, and TikTok skincare detox?

    Learning objectives:
    ✅ Review emerging data comparing isotretinoin monotherapy with isotretinoin plus topical clascoterone in severe acne vulgaris
    ✅ Discuss the potential clinical relevance of combination therapy for clearance, tolerability, and patient experience
    ✅ Explore practical approaches to integrating clascoterone into isotretinoin treatment plans
    ✅ Consider real-world limitations of retrospective data, including confounders, dosing variation, skincare use, and patient selection
    ✅ Reframe acne treatment goals beyond lesion counts to include scarring prevention, satisfaction, and long-term disease control

    🎧 AAD 2026 coverage from the Mile High City. Special thanks Dr. Mohannad Abu-Hilal.

    #SkinAndJointsPodcast #AAD2026 #Dermatology #Acne #AcneVulgaris #Isotretinoin #Clascoterone #Winlevi #DermTwitter #MedEd #DermatologyEducation #SevereAcne #AcneScarring #SkinHealth #ClinicalDermatology #Vodcast #Podcast #HealthcareEducation

    ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

    Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

    As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

    At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

    About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

    Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

    Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

    Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

    Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

    Supported by an IME Grant from SUN Pharma.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    21 mins
  • Sebum Like It Hot: New 52-Week Acne Data from AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz

    Sebum Like It Hot: New 52-Week Acne Data from AAD 2026 with Dr. Renée A. Beach and Dr. Irina Oroz
    Apr 13 2026

    🎙️✨ New Acne Data Just Dropped — and We’re Bringing the Post-Game Analysis from AAD 2026! 🏀

    Live from Denver — the Mile High City — the Skin and Joints Podcast is breaking down new 52-week real-world acne data exploring the impact of clascoterone 1% on sebum reduction, acne improvement, tolerability, and what it actually means in day-to-day dermatology practice.

    Because let’s be honest: in acne care, it’s not just about lesion counts. Patients care about oiliness, shine, pores, irritation, post-inflammatory marks, and whether their treatment routine feels like a science experiment before bed.

    In this episode, Dr. Renée A. Beach and Dr. Irina Oroz (and a mystery guest co-host ;)) join the conversation to unpack the clinical relevance of the data — and why “treat-to-happy” might just be the endpoint patients really care about.

    We also get into the practical side:
    ✅How do you layer clascoterone with retinoids?
    ✅What does sebum reduction actually mean in clinic?
    ✅Is “zero irritation” too good to be true — or reflective of real-world experience?
    ✅And most importantly… is it pronounced sebometer or sebumeter?

    From male acne patients who now have a topical anti-androgen option, to patients who have tried everything, to those who need a tolerable long-term acne strategy — this episode explores where the data meets the real world.

    Learning Objectives:
    ✅ Review new 52-week data on clascoterone 1% and sebum reduction in acne
    ✅ Discuss the clinical relevance of sebum, shine, oiliness, and patient-reported treatment success
    ✅ Evaluate long-term acne outcomes including IGA success, inflammatory and non-inflammatory lesion reduction, and tolerability
    ✅ Explore practical strategies for layering clascoterone with retinoids, benzoyl peroxide, and combo topical therapies
    ✅ Identify patient profiles who may benefit from topical anti-androgen therapy in real-world practice

    ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON

    Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).

    As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).

    At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types

    About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK

    Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.

    Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.

    Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.

    Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.

    Supported by an IME Grant from SUN Pharma.


    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    35 mins
  • Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026

    Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026
    Apr 9 2026
    🎙️ Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive- Part 2 Guests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026 We’re back with Part 2 of our atopic dermatitis double-header with Dr. Marissa Joseph and Dr. Fiona Lovegrove from AAD 2026 in Denver—and this time, we’re getting into the data that always enters the chat when JAK inhibitors in Atopic Dermatitis are mentioned: long-term safety. Our expert faculty unpack fresh 6-year safety data on upadacitinib in moderate-to-severe atopic dermatitis—looking beyond efficacy and into the real-world clinical questions dermatologists face every day: 🧩 Who is the right patient?⚖️ How do we balance real world risk vs benefit?👵 Does anything change when a patient is over 65? Or is it about how risk is really framed?💉 Where does zoster vaccination fit into the treatment conversation? 📊 And how do we contextualize MACE, VTE, malignancy, infections, and herpes zoster without turning nuance into noise? Because let’s be honest: when it comes to JAK inhibitors, the safety conversation doesn’t just knock politely—it pulls up a chair. 🪑 This episode dives into how long-term data can help clinicians move beyond blanket “yes/no” thinking and toward more individualized decision-making: age, comorbidity stacking, dose, baseline risk, quality of life, disease severity, and patient preference all matter. The big takeaway? Decisions in the gray zone—and that’s exactly where expert interpretation matters most. 🎯 Learning Objectives: By the end of this episode, listeners will be able to: Discuss the clinical relevance of long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis.Identify key safety considerations, including herpes zoster, serious infections, MACE, VTE, and malignancy.Describe how age, comorbidities, dose selection, and baseline patient risk influence treatment decisions with oral JAK inhibitors.Explain the role of shared decision-making and risk-benefit communication when treating adolescents, adults, and older patients with AD.Recognize practical considerations around zoster vaccination and routine immunization when initiating JAK inhibitor therapy. 🎧 Tune in for a practical, nuanced, and slightly puppy-interrupted breakdown of what this data actually means for your clinic. #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #Dermatology #JAKInhibitors #Upadacitinib #Rinvoq #EczemaCare #DermTwitter #MedEd #HCPeducation #DermatologyPodcast #Vodcast #ClinicalPearls #SharedDecisionMaking #SkinScience #ADTreatment REFERENCE: Long-Term 6-Year Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis Across Ages: Results From Three Phase 3 Studies ABOUT Dr. Marissa Joseph MD FRCPC TORONTO, ON DERMATOLOGIST AND PEDIATRICIAN Dr. Marissa Joseph is an Associate Professor at the University of Toronto and the Medical Director of the Ricky Kanee Schachter Dermatology Centre at Women’s College Hospital. She also practices at The Hospital for Sick Children (SickKids), where she cares for children with complex skin disease in both clinic and inpatient settings and leads a pediatric laser program. Her clinical work spans general adult, pediatric, and surgical dermatology. Internationally recognized for her expertise in pediatric dermatology, inflammatory skin disorders, and equity, diversity, and inclusion in dermatologic care, Dr. Joseph has authored book chapters and numerous peer-reviewed publications. She has also been honoured for excellence in teaching at the University of Toronto. Her vision for the field is both simple and ambitious: equitable, high-quality dermatologic care for everyone. ABOUT Dr. Fiona Lovegrove MD FRCPC LONDON, ON DERMATOLOGIST Dr. Fiona Lovegrove is a board-certified dermatologist and founder of Lovegrove Dermatology in London, Ontario. She earned her MD and PhD at the University of Toronto, where she also completed her dermatology residency. A Fellow of the Royal College of Physicians and Surgeons of Canada, she holds an academic appointment as Adjunct Professor at the Schulich School of Medicine & Dentistry.Her clinical expertise includes psoriasis, eczema, skin cancer, and complex diseases such as bullous pemphigoid. Actively engaged in research and clinical trials, she has contributed to publications, conferences, national and global advisory boards and is a GRAPPA member. Dr. Lovegrove is committed to providing patient-centered, evidence-based dermatology care. Supported by an IME Grant from ABBVIE.. 📻www.skinandjoints.ca✉️info@skinandjoints.ca Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    Show More Show Less
    28 mins
adbl_web_anon_alc_button_suppression_c
No reviews yet